Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Link
http://link.springer.com/article/10.1186/1471-2407-9-34/fulltext.html
Reference38 articles.
1. Cancer Facts and Figures 2008. American Cancer Society. [ http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf ]
2. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999, 17: 2530-40.
3. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS: Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002, 20: 1368-74. 10.1200/JCO.20.5.1368.
4. Escudier B, Pluzanska A, Koralewski P, for the AVOREN trial investigator: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet. 2007, 370: 2103-11. 10.1016/S0140-6736(07)61904-7.
5. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005, CD001425-1
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas;Urologic Oncology: Seminars and Original Investigations;2019-10
2. Efficacy of targeted therapy for advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials;International braz j urol;2018-04
3. Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma;Urologia Internationalis;2016-10-13
4. The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma;Japanese Journal of Clinical Oncology;2016-06-01
5. Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma;Urologia Internationalis;2016-03-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3